UBS AM
ZBIO

UBS AM’s Zenas BioPharma ZBIO Stock Holding History

UBS AM’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$959K Buy
37,790
+22,267
+143% +$443K ﹤0.01% 2357
2026
Q1 		$303K Buy
15,523
+7,123
+85% +$160K ﹤0.01% 2657
2025
Q4 		$305K Buy
+8,400
New +$276K ﹤0.01% 2412
2025
Q3 		– Sell
-14,900
Closed -$144K – 2661
2025
Q2 		$144K Buy
+14,900
New +$145K ﹤0.01% 2577

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

UBS AM's ZBIO Position: Q2 2026 in Review

UBS AM increased its Zenas BioPharma (ZBIO) stake by 143% in Q2 2026, buying an estimated $443K and bringing the position to 37,790 shares worth $959K. The position accounts for ﹤0.01% of the portfolio, ranked #2357.

UBS AM first reported a position in ZBIO in Q2 2025 and has held it in 4 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • UBS AM held 37,790 shares of Zenas BioPharma worth $959K as of Q2 2026.
  • UBS AM bought 22,267 Zenas BioPharma shares in Q2 2026, an estimated $443K.
  • Zenas BioPharma made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2357 holding.
  • UBS AM first reported a position in Zenas BioPharma in Q2 2025 and has held it in 4 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.